Home Drug IndexClinical Monograph

Metipranolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

DRUG NAME: Metipranolol

Therapeutic Class: Beta-adrenergic blocker (ophthalmic)

Subclass: Non-selective beta-blocker (topical)

Speciality: Ophthalmology

Schedule (India): Schedule H

Route(s): Ophthalmic (topical only)

Formulations Available in India:

Formulation	Strength	Pack Size
Eye drops	0.3%	5 mL bottle

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

⮞ Ocular Hypertension / Primary Open-Angle Glaucoma

Parameter	Recommendation
Starting dose	1 drop of 0.3% solution twice daily in affected eye(s)
Titration	Not usually required; assess IOP after 2–4 weeks
Usual maintenance dose	1 drop twice daily
Maximum dose	1 drop twice daily (higher frequency not shown to improve efficacy)

Clinical Notes:

May be used as monotherapy or in combination with other anti-glaucoma agents (carbonic anhydrase inhibitors, prostaglandin analogues)
Onset of IOP-lowering effect: within 30 minutes
Peak effect: 2–3 hours post-instillation
Instruct patient to apply nasolacrimal occlusion for 1–2 minutes after instillation to minimise systemic absorption

Secondary Indications — Adults Only (Off-label, if any)

Not commonly used for other indications in Indian clinical practice.

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

NOT RECOMMENDED in children under 12 years due to limited safety data and risk of systemic beta-blockade effects.

Secondary Indications — Paediatric Doses (Off-label, if any)

⮞ Paediatric Glaucoma (e.g., Juvenile Open-Angle Glaucoma) — OFF-LABEL

Parameter	Recommendation
Age	≥5 years (avoid below 5 years unless absolutely necessary)
Dose	1 drop of 0.3% in affected eye(s) once or twice daily
Maximum	2 drops/day per eye
Supervision	Paediatric ophthalmologist only

Safety Monitoring:

Heart rate and rhythm (risk of bradycardia)
Respiratory status (bronchospasm risk, especially in children <5 years)
Growth and feeding patterns
Blood pressure monitoring

Evidence basis: Limited paediatric data; extrapolated from adult studies and specialist practice protocols

Statement: Not recommended below 5 years of age except under specialist supervision with documented failure of alternative agents.

RENAL ADJUSTMENT

Renal Status	Recommendation
All stages (including ESRD)	No dosage adjustment required

Rationale: Minimal systemic absorption following ophthalmic administration; negligible renal excretion of absorbed fraction.

HEPATIC ADJUSTMENT

Severity	Recommendation
Mild impairment	No adjustment required
Moderate impairment	No specific adjustment; monitor for systemic effects
Severe impairment	Use with caution; risk of systemic beta-blockade if absorption occurs; close cardiovascular monitoring advised

CONTRAINDICATIONS

Hypersensitivity to metipranolol, other beta-blockers, or any excipients
Sinus bradycardia (<50 bpm)
Second or third-degree atrioventricular block (unless permanent pacemaker in situ)
Uncontrolled or decompensated cardiac failure
Cardiogenic shock
Bronchial asthma (current or history)
Severe chronic obstructive pulmonary disease with bronchospastic component
Sick sinus syndrome

CAUTIONS

Mild to moderate COPD without bronchospastic component — monitor respiratory function
Diabetes mellitus — may mask adrenergic symptoms of hypoglycaemia (tremor, tachycardia)
Thyrotoxicosis — may mask symptoms of thyroid storm
Myasthenia gravis — potential worsening of muscle weakness
Concurrent use of systemic beta-blockers — additive systemic effects
Peripheral vascular disease — may exacerbate symptoms
History of severe anaphylaxis — may diminish response to epinephrine
Corneal disease — benzalkonium chloride preservative may worsen epithelial toxicity
Prior to intraocular surgery — consider discontinuation if feasible

PREGNANCY

Parameter	Details
Safety category	Limited human data; avoid unless clearly necessary
Risk	Beta-blockers may cause fetal bradycardia, hypoglycaemia, and growth restriction
Preferred alternatives	Brimonidine (after first trimester), latanoprost — with obstetric input
When permissible	Only when IOP control is essential and alternatives unsuitable; involve maternal-fetal medicine specialist
Monitoring	Fetal heart rate monitoring if used in third trimester; neonatal observation for 48–72 hours post-delivery

LACTATION

Parameter	Details
Compatibility	Likely compatible with breastfeeding when nasolacrimal occlusion technique used
Drug levels in milk	Expected to be very low due to minimal systemic absorption
Preferred alternatives	Timolol ophthalmic (more safety data in lactation)
Infant monitoring	Observe for bradycardia, poor feeding, lethargy, respiratory depression

ELDERLY

Parameter	Recommendation
Starting dose	No dose modification required
Titration	Cautious if concurrent systemic beta-blocker or cardiovascular medications
Special risks	Bradycardia, orthostatic hypotension, confusion, depression (rare but reported with systemic absorption)
Monitoring	Heart rate, blood pressure, cognitive function in long-term users

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect	Management
Systemic beta-blockers (propranolol, atenolol, metoprolol)	Additive bradycardia, hypotension, heart block	Avoid combination or monitor HR and BP closely
Verapamil, diltiazem (systemic)	Increased risk of AV block, bradycardia, cardiac depression	Avoid; if essential, cardiac monitoring required
Digitalis glycosides (digoxin)	Additive bradycardia, AV conduction delay	Monitor heart rate; consider ECG surveillance
Class I antiarrhythmics (quinidine, flecainide)	Additive negative inotropic and dromotropic effects	Avoid concurrent use
Amiodarone	Profound bradycardia, hypotension	Avoid combination

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Management
Clonidine	Rebound hypertension if clonidine discontinued abruptly	Discontinue beta-blocker several days before tapering clonidine
Insulin, sulfonylureas	Masking of hypoglycaemia warning symptoms	Educate patient; frequent blood glucose monitoring
CYP2D6 inhibitors (fluoxetine, paroxetine)	Potential for increased systemic beta-blocker effect	Monitor for bradycardia
Other topical ophthalmic agents	Dilution effect, altered absorption	Allow 5–10 minutes between different eye drops
NSAIDs	May reduce antihypertensive effect if systemic absorption occurs	Clinical significance low for topical beta-blockers

COMMON ADVERSE EFFECTS

Transient ocular stinging or burning upon instillation
Blurred vision (temporary)
Conjunctival hyperaemia
Foreign body sensation
Dry eyes
Tearing or lacrimation
Blepharitis

SERIOUS ADVERSE EFFECTS

Adverse Effect	Clinical Action
Symptomatic bradycardia, AV block	Discontinue immediately; cardiology referral
Bronchospasm, asthma exacerbation	Stop drug; manage with bronchodilators; avoid rechallenge
Severe hypotension	Discontinue; supportive care
Stevens-Johnson syndrome/TEN (very rare)	Immediate discontinuation; dermatology and ICU referral
Severe allergic conjunctivitis or periorbital oedema	Discontinue; switch to alternative class
Depression, confusion (especially elderly)	Consider discontinuation; psychiatric evaluation if severe

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Intraocular pressure (IOP), heart rate, blood pressure, respiratory assessment
After initiation	Recheck IOP at 2–4 weeks; HR weekly if on concomitant systemic beta-blocker
Long-term	IOP every 3–6 months; annual fundoscopy and visual field assessment; monitor for ocular surface toxicity (especially if using preserved formulation)

BRANDS AVAILABLE IN INDIA

Brand Name	Manufacturer	Strength
Optipranolol Eye Drops	Bausch + Lomb	0.3% (5 mL)

Note: Limited brand availability in India; may require procurement through specific distributors.

PRICE RANGE (INR)

Parameter	Details
Approximate cost	₹50–100 per 5 mL bottle
NLEM status	Not included under NLEM
Availability	Primarily private ophthalmic practice; limited hospital formulary inclusion

CLINICAL PEARLS

Alternative agent: Less commonly prescribed than timolol; consider when patient shows intolerance or inadequate response to timolol
Nasolacrimal occlusion technique: Always instruct patients to press inner canthus for 1–2 minutes post-instillation to reduce systemic absorption
Asthma precaution: Avoid even topical use in asthmatics — bronchospasm reported with ophthalmic beta-blockers
Combination therapy: Can be combined with prostaglandin analogues or carbonic anhydrase inhibitors for additive IOP reduction
Elderly monitoring: Watch for subtle mood changes, fatigue, or depression on chronic use
Preservative sensitivity: For patients with ocular surface disease, preservative-free alternatives (if available) or switch to another class may be preferable

VERSION

RxIndia v0.1 — 19 Feb 2026

REFERENCES

CDSCO approved prescribing information
Indian Pharmacopoeia/National Formulary of India
AIIMS Drug Formulary
API Textbook of Medicine
Indian Ophthalmic Clinical Practice Guidelines
Standard textbooks of clinical pharmacology (for cross-validation)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...

Metipranolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

DRUG NAME: Metipranolol

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

Secondary Indications — Adults Only (Off-label, if any)

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Secondary Indications — Paediatric Doses (Off-label, if any)

RENAL ADJUSTMENT

HEPATIC ADJUSTMENT

CONTRAINDICATIONS

CAUTIONS

PREGNANCY

LACTATION

ELDERLY

MAJOR DRUG INTERACTIONS

MODERATE DRUG INTERACTIONS

COMMON ADVERSE EFFECTS

SERIOUS ADVERSE EFFECTS

MONITORING REQUIREMENTS

BRANDS AVAILABLE IN INDIA

PRICE RANGE (INR)

CLINICAL PEARLS

TAGS

VERSION

REFERENCES

Clinical Responsibility

Is this information helpful?

RxIndia

Metipranolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

DRUG NAME: Metipranolol

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

Secondary Indications — Adults Only (Off-label, if any)

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Secondary Indications — Paediatric Doses (Off-label, if any)

RENAL ADJUSTMENT

HEPATIC ADJUSTMENT

CONTRAINDICATIONS

CAUTIONS

PREGNANCY

LACTATION

ELDERLY

MAJOR DRUG INTERACTIONS

MODERATE DRUG INTERACTIONS

COMMON ADVERSE EFFECTS

SERIOUS ADVERSE EFFECTS

MONITORING REQUIREMENTS

BRANDS AVAILABLE IN INDIA

PRICE RANGE (INR)

CLINICAL PEARLS

TAGS

VERSION

REFERENCES

Clinical Responsibility

Is this information helpful?